Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY 2,336.50
+38.00 (1.65%)
Oct 1, 2025, 3:30 PM JST
Kyowa Kirin Revenue
Kyowa Kirin had revenue of 125.93B JPY in the quarter ending June 30, 2025, a decrease of -1.16%. This brings the company's revenue in the last twelve months to 493.24B, up 3.62% year-over-year. In the year 2024, Kyowa Kirin had annual revenue of 495.56B with 12.06% growth.
Revenue (ttm)
493.24B
Revenue Growth
+3.62%
P/S Ratio
2.44
Revenue / Employee
87.01M
Employees
5,669
Market Cap
1,203.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | 318.35B | 12.53B | 4.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.21B |
| HOYA Corporation | 876.09B |
| Takeda Pharmaceutical Company | 4,480.25B |
| Daiichi Sankyo Company | 1,924.68B |
| Otsuka Holdings | 2,401.70B |
| Terumo | 1,037.94B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |
Kyowa Kirin News
- 21 days ago - Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis - Benzinga
- 21 days ago - Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab - GuruFocus
- 21 days ago - Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug - Seeking Alpha
- 22 days ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab ... - GuruFocus
- 22 days ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 ASCEND ... - GuruFocus
- 6 weeks ago - Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers - GlobeNewsWire
- 2 months ago - Kyowa Kirin Co., Ltd. (KYKOF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress - PRNewsWire